5th rna-seq san francisco agenda

April 25 -27, 2017, San Francisco

5th

Researched & Developed By:

Realize the Practical Applications of RNA-Seq to Supercharge Discovery & Development of New Drugs, Targets & Biomarkers

Tel: +1 212 537 5898 | Email: [email protected] RNA-Seq Forum

www.rna-seqsummit.com

Hear From 18+ World Class Scientists Including:

Jin JenCo-Director, Genome Analysis Core Medical Genome Facility Mayo Clinic

Paul RejtoExecutive Director & Head of Translational ResearchPfizer Inc.

Chris MasonAssociate ProfessorWeill Cornell Medicine

Garry NolanRachford & Carlota Harris ProfessorStanford University

Paul KayneDirector of GenomicsBristol Myers Squibb Co

Program PartnersHosting Partner Spotlight Partners Expertise Partner Exhibitor

2017

Excellent panel of speakers providing a comprehensive overview of the field in just 2 days

Gereon Lauer, Associate Director Clinical Biomarker,

Vertex Pharmaceuticals

Book now and save up to $500

1

3

2

4

5

RNA-Seq 2017 San Francisco | April 25 -27, 2017

Tel: +1 212 537 5898 Email: [email protected]

www.rna-seqsummit.com RNA-Seq Forum

2017

Evaluate the tools being applied to optimize the integrative analysis of high capacity and throughput studies supporting drug discoveries

Optimize your biomarker discovery through high value RNA-Seq strategies exploring gene expression profiles that detail specific impacts on health and disease

Great meeting. Very focused and interesting.

University of Turin

The conference was well-run. Speakers were well-selected over a broad but useful range.

NIST

Very carefully chosen content and very informative. The right balance between industry and academia. I enjoyed all presentations and discussion panels.

Millennium

Develop analytical strategies incorporating machine learning algorithms that integrate high-throughput data and infer RNA biogenesis and function for target and pathway validation

Harness the protocols being utilized to process and integrate RNA-Seq data from public platforms and how they are being applied in large scale omic studies to advance progression in disease research

Hear What Previous Attendees Have To Say:

Discover and validate analytical tools being utilized for enhanced transcriptome data interpretation in both basic research and clinical applications

Engage in debate with bioinformaticians and biologists to streamline the RNA-Seq process from the bench to the computer

Top 10 Reasons to Attend RNA-Seq 2017

Evaluate the tools being applied for the successful study of spatial transcriptomics, achieving better resolution of tumour biology, composition and IO interactions

Uncover new insights for splicing modulating compounds with the latest developments in RNA-Seq technology

Understand how single cell RNA-Seq is being implemented into the clinical setting to advance the precision medicine paradigm

Discover emerging trends beyond single cell sequencing and how they are being applied to drug development, research and clinic environments

Welcome to the 5th Annual RNA-Seq SummitDiscover the Latest Developments in the Applications of RNA-Seq

RNA-Seq 2017 is a vital forum for expert biologists and bioinformaticians to come up to speed with the latest advances in applying RNA-Seq technologies and analytical tools from bench to bedside.

This year’s agenda, designed by fore-thinkers in the industry, gives a greater focus to emerging technologies and their clinical applications. It will provide you with new solutions to key challenges including roadblocks in applying single cell technology in the clinic, the integration and mining of RNA-Seq data for drug discovery research, and novel methods to understand the impact of tissue composition and cellular interactions.

Join your peers in an in-depth discussion of data driven case studies to uncover how to fully utilize the technology, and accurately interpret vast amounts of data to unpick the complexity of the transcriptome.

6

8

7

9

10

SpeakersBin Tian Professor of Microbiology, Biochemistry & Molecular Genetics Rutgers Cancer Institute of New Jersey

Garry Nolan Rachford & Carlota Harris ProfessorStanford University

Jin Jen Co-Director, Genome Analysis Core Medical Genome Facility Mayo Clinic

Chris Mason Associate Professor Weill Cornell Medicine

Vanessa Peterson, Associate Principal Scientist Merck

Chung-Chau Hon Research ScientistRIKEN Center for Life Science Technologies

Chris Bunker, VP of Business DevelopmentAdvanced Cell Diagnostics, Inc.

Maria Campo,Field Applications Manager, NGS Roche Sequencing

Joost Groot Scientist, Computational Biology Biogen

Paul Diehl Chief Operating Officer, Cellecta

Paul Rejto Executive Director & Head of Translational Research Pfizer Inc.

Paul Kayne Director, Genomics Bristol-Myers Squibb Co

Rob Currie Chief Technology Officer UCSC Genomics Institute

Rob Kuhn Associate Director UC Santa Cruz Genome Browser

Shanrong Zhao Director, Computational Biology & Bioinformatics Pfizer Inc.

Thomas Wu Principal Scientist, Bioinformatics & Computational Biology Genentech

Michael StadniskyCEOFlowJo, LLC

Xiang (Sean) Yao Principal Scientist, Computational Biology Janssen Pharmaceuticals of Johnson & Johnson

Yoseph Barash Assistant ProfessorPerelman School of Medicine University of Pennsylvania

Yi Xing Professor, Microbiology, Immunology & Molecular GeneticsUCLA

Yuka Imamura Director, Penn State Hershey Genome Sciences Facility & Assistant Professor of Biochemistry, Molecular Biology & Pharmacology Penn State College of Medicine




2017




2017

Conference Day One | Wednesday, April 26, 2017

Paul Kayne, Director, Genomics, Bristol-Myers Squibb Co

8.20 Chairman’s Opening Remarks: An Overview of the RNA-Seq Field & Looking Towards the Next Generation of RNA Technologies

Understanding the Transcriptome Through Emerging Sequencing Concepts

Chung-Chau Hon, Research Scientist, RIKEN Center for Life Science Technologies

8.30 A 5’Complete Transcriptomic Atlas & its Applications in Studies of Long Non-Coding RNA• Generating a novel and comprehensive catalog of high-confidence 5’complete human long

non-coding RNA (lncRNA) genes by integrating FANTOM5 CAGE data with RNA-Seq

• Clarifying the heterogeneity of lncRNAs to determine the derivation of intergenic lncRNAs as enhancer-like regions rather than from promoters

• Incorporating genetic and expression data to identify potential roles in diseases and gene regulation for thousands of lncRNAs

Shanrong Zhao, Director, Computational Biology & Bioinformatics, Pfizer Inc.

9.00 A Head-to-Head Comparison Between Total vs. mRNA-Sequencing• Evaluating these two sequencing protocols

• Exploring the real advantages and disadvantages of total RNA-Seq

Paul Diehl, COO, Cellecta

9.30 Spotlight Presentation: Sensitive & Comprehensive Genome-Wide Expression Profiling Directly from Total RNA• Gene expression analysis of target model systems is required to understand the genetic

changes associated with biological responses

• We show that the combination of RT-PCR amplification with next generation deep sequencing provides a more sensitive and robust approach for transcriptome profiling than standard RNA-Seq

• The RT-PCR step with targeted primers enables the profiling assay to generate highly specific data, even with mouse xenograft models, directly from total RNA

Bin Tian, Professor of Microbiology, Biochemistry & Molecular Genetics, Rutgers Cancer Institute of New Jersey


Shanrong Zhao, Director, Computational Biology & Bioinformatics, Pfizer Inc.

9.45 Panel Discussion: Specialized RNA Sequencing Methods with Applications to RNA Life Cycles & Drug Development• Discussing a role for nascent RNA-Seq as a Diagnostic and Prognostic Tool

• Analyzing 3’vs. 5’ sequencing, applications utility and robustness

• Understanding how to map polymerase on the template

• Realizing the benefits from a low posttranscriptional noise

10.30 Morning Refreshments & Speed Networking




2017

Understanding RNA Processing to Further Drug Development

Vanessa Peterson, Associate Principal Scientist, Merck

11.30 Harnessing Single Cell RNA-Seq to Understand the Impact of Tumour Composition & IO Interactions• Identifying mechanisms that differentiate responders from non-repsonder to develop

a deep knowledge of the phenotype and function of immune and cancer cells pre/post treatment

• Exploring how single cell RNA-Seq approaches were utilized to allow unsupervised clustering of cells into genotypically/phenotypically related populations

• Characterizing the ‘immunotype’ of these discrete subsets through RNA-Seq to allow for the reconstruction of signaling networks between malignant and non-malignant cell populations

Michael StadniskyCEOFlowJo, LLC

12.00 The Command Line is Compromise: A New Paradigm for Single Cell RNA-Seq Analysis• The Command Line is Compromise: A New Paradigm for Single Cell RNA-Seq Analysis• We have developed a new analysis paradigm for gene expression analysis using

bidirectional cell population-gene set visualization, which enables bench scientists to derive insight from RNA-Seq data, particularly single cell RNA-Seq; share their gene sets and discovery process reproducibly; pre-process and normalize how they see fit; and requires no command line or bioinformatics expertise.

• Using a publicly available data set from a study of metastatic melanoma and intuitive supervised and unsupervised analyses, we show that layers of depth beyond traditional immunological phenotyping are possible and show reduction in analysis time from >4 hours to less than 30 seconds.

• We present an innovative, rapid, intuitive analysis paradigm to harness the power of single cell RNA-Seq and gene expression studies.

Xiang (Sean) Yao, Principal Scientist, Computational Biology, Janssen Pharmaceuticals of Johnson & Johnson

12.30 Integration & Mining of RNA-Seq Data for Drug Discovery Research• Understanding how integrating public and internal data provides large sample size and

independent validation therefore more accurate results

• Building high capacity and throughput infrastructure supporting integrative analysis and drug discoveries

1.00 Lunch & Networking

Overcoming Challenges in Drug Development Through RNA-Seq

2.00 QIAGEN Plenary Presentation: Title to be Confirmed

Bin Tian, Professor of Microbiology, Biochemistry & Molecular Genetics, Rutgers Cancer Institute of New Jersey

2.30 Using 3’ Sequencing to Understand Human Diseases• Exploring the mechanism utility and consequence of dysregulation of 3’ termination in

disease pathogenesis and spread

• Understanding how 3’ regulation is related to health and disease

• Analyzing recent data giving insight into cancer, metastasis and neurological diseases




2017

Maria Campo,Field Applications Manager, NGS, Roche Sequencing

3.00 KAPA RNA HyperPrep: Improved Performance with Degraded Inputs & Tumor Profiling ApplicationsHigh resolution RNA analysis using next-generation sequencing (RNA-seq) is a rapidly growing application in disease research. The quality of RNA extracted from biological specimen is highly variable and yields are often low, thus impacting the ability to generate high-quality sequencing libraries.In this presentation, we will: • Discuss improvements in the library preparation workflow • Provide guidance on working with low input & degraded samples • Demonstrate improved detection of differential expression in tumor profiling

3.30 Afternoon Refreshments & Dedicated Poster Session

Understanding RNA Processing to Further Drug Development

Yoseph Barash, Assistant Professor, Perelman School of Medicine University of Pennsylvania

4.00 Integrating Big Data for RNA Processing - From Computational Modeling, Through the Wet Lab, to Patients• Review state of the art in RNA splicing detection, quantification, and prediction algorithms• Showcase examples of how machine learning algorithms are used to derive new findings

in RNA processing and disease associated transcript variations that are then verified experimentally

• Address challenges and directions in Big Data analysis in the field

Yi Xing, Professor, Microbiology, Immunology, & Molecular Genetics, UCLA

4.30 Elucidating Transcriptome Complexity & Alternative Isoform Variation Using Massive RNA-Seq Data• Demonstrating RNA-Seq as a powerful technology for transcriptome-wide profiling of

mRNA isoform variation resulting from alternative RNA processing and modifications

• Identifying novel biomarkers and therapeutic targets of cancer through global analysis of mRNA isoform variations in clinical cancer RNA-Seq data sets

• Exploring robust and efficient statistical and computational methods required for isoform analysis using massive RNA-Seq datasets

5.00 Round Tables


5.30 Chairman’s Closing Remarks

5.35 Close of Day One

QIAGEN Sponsored Evening Reception

The Utility of Non-Coding RNA in Drug Development

What’s Necessary for

Clinical Validation: Controlling

the Statistical Variables

RNA Based Modifications:

Exploring a Potential Role in Drug Development

Data Processing & Informatics

Management

Rob Currie, Chief Technology Officer, UCSC Genomics Institute


Garry Nolan, Rachford & Carlota Harris Professor, Stanford University

Yi Xing, Professor, Microbiology, Immunology, & Molecular Genetics, UCLA

1 2 3 4




2017

Looking Towards the Future for RNA-Seq

Thomas Wu, Principal Scientist, Bioinformatics & Computational Biology, Genentech

9.00 Designing NGS Alignment & Analysis Software for Modern Computer Processors• Exploring the new capabilities of modern computer processors such as vector arithmetic

and core number and the applications to RNA-Seq

• Developing a gold standard for alignment and analysis to guide drug discovery and development

• Applying metatranscriptomics and interpreting gene expression profiles to detail specific impacts on health and disease

Chris Mason, Associate Professor, Weill Cornell Medicine

9.30 RNA-Sequencing for Earth, the Space Station, & Beyond• Exploring improved computational methods for novel detection of modified nucleic acids

• Assessing whether space-based sequencing is possible and robust

• Improving scientific research on the ISS through advancements in microbe identification, disease diagnostics, and collection of real-time genomic data

Paul Rejto, Executive Director & Head of Translational Research, Pfizer Inc.

10.00 Deconvoluting RNA-Sequencing Profiles into Cellular Subtypes for Oncology• Understanding that cancer immunotherapies are highly variable from patient to patient

and that RNA-Seq can provide novel insights into cancer immune subtypes

• Realizing the emerging role of RNA-Seq in developing predictive and early pharmacodynamics biomarkers for cancer immunotherapy

Chris Bunker, VP of Business Development Advanced Cell Diagnostics, Inc.

10.30 Transcriptomes in Context: Validation of RNAseq Discoveries with Tissue-based Cell-specific Expression Analysis by RNAscope ISH • RNAscope probes for any or every novel RNAseq transcript discovery – 2 weeks + 1 day

from sequence to in situ expression data

• Equivalent sensitivity of RNAscope and RNAseq: Single-molecule detection of any RNA in intact fixed tissue

• In situ expression analysis with single-cell resolution to verify single-cell RNAseq

• Novel mutation detection, prevalence and tissue heterogeneity assessment with BaseScope ISH

11.00 Morning Refreshments

Exploring Single Cell Technology Advances in a Clinic Setting


11.30 Single Cell Deep Profiling of Cancer & Immunity• Identifying the immune-phenotypes of different types of cancer by applying computational

methods on large scale RNA-Seq data

• Exploring how cancer immune-phenotyping supports patient stratification and biomarker research in cancer immunotherapy

• Understanding the relationship between cancer immune-phenotypes with immune genes and signalling pathways based on RNA-Seq expression profiling

12.00 BioRad Plenary Presentation: Title to be Confirmed

12.30 Lunch & Networking

Conference Day Two | Thursday, April 27, 2017




2017

Jin Jen, Co-Director, Genome Analysis Core Medical Genome Facility, Mayo Clinic

1.30 Clinical Case Study: Single Cell RNA-Seq to Dissect Tumor Heterogeneity in Multiple Myeloma• Evaluating clinical and common molecular features of multiple myeloma

• Developing strategies for optimized single cell whole transcriptome profiling

• Addressing data normalization and analysis considerations

• Understanding genomic heterogeneity underlying multiple myeloma progression

Jin Jen, Co-Director, Genome Analysis Core Medical Genome Facility, Mayo Clinic

Rob Currie, Chief Technology Officer, UCSC Genomics Institute


2.00 Panel Discussion: Successfully Implementing RNA-Seq into the Clinic• Understanding the approval standards for clinical applications of RNA-Seq

• Revamping the regulatory system to support the innovation and application of RNA-Seq in the clinic

• Defining the regulatory framework to identify the procedures for delivering clinically useful RNA-Seq products

• How to best analyze, interpret and present RNA-Seq data to maximize a clinically relevant output

• Incorporating RNA-Seq into clinical management and practices: Identifying how to best utilize RNA-Seq in the clinic

• How RNA sequencing workflow and applications are making it into routine clinical testing

2.45 Afternoon Refreshments

Applying RNA-Seq to Systems Biology & Precision Medicine

Joost Groot, Scientist, Computational Biology, Biogen

3.15 Next-Generation Sequencing & Omics Technologies for Biotherapeutic Manufacturing Engineering & Systems Biology• Using targeted RNA-Seq of biotherapeutic mRNA sequence to ensure candidate

production clones are free of mutations

• Developing Omics analyses for CHO bioprocesses; RNA-Seq on a genome and annotation with intermediate resolution

• Understanding how targeted DNA/genome sequencing can be used to characterize integration sites of the biotherapeutic transgene

Yuka Imamura, Director, Penn State Hershey Genome Sciences Facility & Assistant Professor of Biochemistry, Molecular Biology & Pharmacology, Penn State College of Medicine

3.45 Identification of Exosome microRNA Biomarker for Parkinson’s Disease• Optimizing the purification workflow for exosomal microRNA from various body fluids

• Discussing the effect of exosome enrichment that is derived from the brain

• Revealing the preliminary result of microRNA biomarker finding for Parkinson’s disease


4.15 Chairman’s Closing Remarks

4.20 End of Day Two & Close of Conference




2017

The concept of a liquid biopsy has been around for some time, but is now fast becoming the leading technology for new diagnostics to detect early stage cancer resulting in more successful treatment, and to monitor cancer progression after treatment. While much of the focus in liquid biopsy has been on sequencing the DNA circulating in the patient’s blood, a recent paper in Nature Cell Biology entitled “Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver” researchers are focusing on exosomes circulating in the bloodstream; specifically the RNA contained within these exosomes.

Pancreatic cancer is one of the most lethal cancers due in part to the difficulty in early diagnosis and treatment. Researchers believe sequencing RNA from tumor derived exosomes circulating in the patient’s blood could lead to early diagnosis and treatment. This workshop will include in-depth coverage of the bioinformatics solutions used to analyze and interpret RNA-sequencing results from these exosome experiments providing additional hypothesis on regulatory networks and potential isoforms of biological significance.

By attending this workshop you learn about and discuss the following:

• Take a deep dive and understand how to optimize the analysis of RNA-sequencing results to get the most out of each RNA-seq experiment

• Standardize RNA-sequencing data analysis using industry leading algorithms and statistical testing

• Understand scalable approaches to sequencing data analysis and optimize the ROI across the organization for sequencing experiments

• Evaluate a biologist approach to streamlining R NA-sequencing alignment and analysis using configured workflows for the fast track to biological interpretation

• Analyze exosome gene expression signatures to pinpoint significant genes associated with early detection of pancreatic cancer

QIAGEN 2017 Workshop to be confirmed

QIAGEN 2016 Workshop: Transcriptome Analysis of Pancreatic Cancer Exosomes Reveal Pathways & Biological Processes Involved in Metastatic ProgressionDate: April 25, 2017 | Time: 9.00am – 12.00pm

Pre-Conference Workshop A

The UCSC Genome Browser is a widely used platform for access to genomic data provided by laboratories around the world. When combined with user-supplied data, it is possible to discern complicated relationships among datasets as disparate as gene predictions, gene expression, regulation, evolutionary conservation, and known variation at all scales from single-base to large copy-number variants.

This workshop will provide you with a basic guide to: • Familiarize yourself with the essential features within

the Browser and how to get around in it• Utilize multiple datasets from public sources as well as

local user data

• Explore associated tools enabling the querying, filtering and rapid visualization of data

A Fundamental Guide to the UCSC Genome BrowserDate: April 25, 2017 | Time: 9.00am – 12.00pm

Robert Kuhn received his PhD at the University of California, Santa Barbara in Biochemistry and Molecular Biology, where he studied the centromeres of yeast. Following a postdoctoral at UC Berkeley/USDA Plant Gene Expression Center, he taught biochemistry, molecular biology and genetics at UC Santa Cruz. He joined the UCSC Genome Browser project in 2003, where he is now Associate Director. The Genome Browser is a widely used visualization tool giving access to the genomes of human and more than one hundred other animals. Dr. Kuhn’s responsibilities include enabling researchers through teaching the Genome Browser in workshops and seminars and learning from them how to improve the Browser, including identification and integration of useful new datasets.

Workshop leaderRob Kuhn, Associate Director, UC Santa Cruz Genome Browser

Pre-Conference Workshop B

CHOOSE A OR B




2017

Detection, Quantification, & Visualization of Splicing Variations from RNA-Seq Data Date: April 25, 2017 | Time: 1.00 – 4.30pm

Yoseph Barash is a computational biologist who works on predictive models to understand RNA biogenesis, its regulation, and its role in human disease. His lab develops machine learning algorithms that integrate genomic and genetic data, followed by wet lab experimental verifications. Yoseph did his Ph.D. in machine learning under Prof. Nir Friedman at the Hebrew University, and his postdoctoral work with Prof. Ben Blencowe and Prof. Brendan Frey at the University of Toronto, focusing on alternative splicing of genes. His dry and wet lab work involves three main themes that pose computational, engineering, and experimental challenges: Deriving new mechanistic insights into RNA biogenesis; Applying the predictive algorithms for RNA processing the lab develops to the study of human disease and phenotypic diversity; Developing software tools that allow the greater scientific community to employ the lab’s algorithms.

Workshop leaderYoseph Barash, Assistant Professor, Perelman School of Medicine University of Pennsylvania

Pre-Conference Workshop C

Alternative splicing of genes is a key contributor to transcriptome variations and numerous disease.

There are many high-throughput experimental techniques nowadays that allow us to measure the expression of genes at exonic resolution, and where factors that regulate RNA splicing bind. These experiments, routinely executed, are quickly accumulating, creating a Big Data deluge problem. Specifically, these experiments are mostly performed separately, only to be “integrated” manually as a list of tracks on a genome browser.

In this workshop, we will review:• Best practices for detecting, quantifying and visualizing gene

splice variants and differential splicing from RNA-Seq

• Different scenarios ranging from small datasets w/wo replicates to large heterogeneous datasets containing hundreds or thousands of samples from patients and controls

• Most of the workshop will focus on the pipelines and algorithms we developed in our lab for these tasks (MAJIQ, MAJIQ-HET), with a comparison to other tools/pipelines such as MISO, rMATS, SUPPA, RSEM, CuffDiff

• Emphasis will be given to how you can evaluate these tools on your own data and best practices

The UCSC Genome Browser is a widely used platform for access to genomic data provided by laboratories around the world. When combined with user-supplied data, it is possible to discern complicated relationships among datasets as disparate as gene predictions, gene expression, regulation, evolutionary conservation, and known variation at all scales from single-base to large copy-number variants.

The Advanced Guide to the Genome Browser will explore:

• How to load and visualize RNA-Seq data into the Browser

• Utilizing the Table Browser to extract and visualize peak locations from those data

• How exon-only view enhances the view of RNA-Seq data by removing non-coding regions from the display

• Exporting lists of genes or known variants from selected regions using several different Browser tools, including the Data Integrator

An Advanced Users Guide to the UCSC Genome BrowserDate: April 25, 2017 | Time: 1.00 - 4.30pm

Robert Kuhn received his PhD at the University of California, Santa Barbara in Biochemistry and Molecular Biology, where he studied the centromeres of yeast. Following a postdoctoral at UC Berkeley/USDA Plant Gene Expression Center, he taught biochemistry, molecular biology and genetics at UC Santa Cruz. He joined the UCSC Genome Browser project in 2003, where he is now Associate Director. The Genome Browser is a widely used visualization tool giving access to the genomes of human and more than one hundred other animals. Dr. Kuhn’s responsibilities include enabling researchers through teaching the Genome Browser in workshops and seminars and learning from them how to improve the Browser, including identification and integration of useful new datasets.

Workshop leaderRob Kuhn, Associate Director, UC Santa Cruz Genome Browser

Pre-Conference Workshop D CHOOSE C OR D




2017

Partnership Opportunities

To become a partner contact Diane McKenna, Commercial Director, Genomics. Tel: +1 212 537 5898 Email: [email protected]

Cellecta

Cellecta provides high-throughput loss-of-function genetic screening services for the discovery and functional characterization

of novel therapeutic targets. We offer pooled lentiviral shRNA, CRISPR, and barcode libraries; pooled library screening and analysis by NGS; targeted RNA-Seq for biomarker discovery; lentiviral reagents; and stable cDNA, shRNA, and CRISPR constructs and isogenic cell lines.

www.cellecta.com

Spotlight Partner

FlowJo

FlowJo, LLC is a privately owned life sciences informatics company in Ashland, Oregon. Based on technology developed at Stanford, the company was founded in 1997 and provides the leading analysis platform for single cell flow cytometry analysis. Their software innovations in single cell sequencing and laboratory collaboration accelerate discovery and high-throughput single cell biology.

www.FlowJo.com

Spotlight Partner

Advanced Cell Diagnostics

Advanced Cell Diagnostics, Inc. (ACD, a Biotechne brand) provides innovative RNA analysis solution that redefines cell- and tissue-based gene analysis for researchers in academic, biotechs and pharmaceutical companies. ACD provides services and products based on RNAscope® assay, the most advanced RNA in situ hybridization (ISH) assay based on this proprietary technology with signal amplification and simultaneous background noise suppression which advances RNA analysis in tissues and cells. Unique to this technology, the RNAscope® assay delivers quantitative, sensitive and specific molecular detection of RNA species on a cell-by-cell basis with morphological context in a robust assay.

www.acdbio.com

Expertise Partner

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Consolidated under the Dutch holding Qiagen N.V., the company operates more than 35 offices in over 20 countries.

Hosting Partner

Dolomite

Dolomite develops and manufactures innovative, open and versatile droplet systems for handling tens of thousands of single cells. Applications include high throughput single cell RNA sequencing, T Cell Receptor sequencing, high throughput antibody isolation, and encapsulation

of cells in hydrogel beads for culture or enzymatic reactions. We offer modular, scalable systems ideal for Single Cell RNA-Seq and a range of chips, and installation and training.

www.dolomite-microfluidics.com

Bio-Rad

Bio-Rad Laboratories, Inc. designs, manufactures, and distributes a broad

range of innovative tools and services to the life science research and clinical diagnostics markets. Founded in 1952, Bio-Rad has a global team of more than 7,750 employees and serves more than 100,000 research and industry customers worldwide through the company’s global network of operations.

www.bio-rad.com

Roche

Headquartered in Pleasanton, California, the Roche Sequencing Unit is focused on developing novel sequencing technologies and

products to support innovation in clinical research applications. Our goal is to develop assays for sequencing, and refine sequencing techniques to advance sequencing technologies that will deliver truly differentiated clinical value.

www.roche.com

Program Partner

Program Partner

Exhibitor

www.qiagen.com

Industry

Register & Pay before Friday March 17, 2016 Standard Prices

Conference + 2 workshops $3597 (save $500) $3797 (save $300)

Conference + 1 workshop $3098 (save $300) $3198 (save $200)

Conference only $2499 (save $200) $2699

Workshops (each) $699

Academics & Not For Profits

Register & Pay before Friday March 17, 2016 Standard Prices

Conference + 2 workshops $1957 (save $500) $2057 (save $400)

Conference + 1 workshop $1738 (save $300) $1838 (save $200)

Conference only $1519 (save $100) $1619

Workshops (each) $419

PricingRegisterwww.rna-seqsummit.com/register/ Tel: +1 212 537 5898 Email: [email protected]: Hanson Wade 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU

• 10% discount – 3 delegates • 15% discount – 4 delegates • 20% discount – 5 or more delegates*Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Team Discounts* Top 3 Benefits of Attending

1

2

3

Discover emerging trends beyond single cell sequencing and how they are being applied to drug development, research and clinic environments

Evaluate and validate analytical tools being utilized for enhanced transcriptome data interpretation in both basic research and clinical applications

Engage in debate with bioinformaticians and biologists to streamline the RNA-Seq process from the bench to the computer

Venue

Hyatt Regency San Francisco Airport 1333 Bayshore Highway, Burlingame, California USA, 94010www.sanfranciscoairport.regency.hyatt.com

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the four-teenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

TERMS & CONDITIONS

Please note: Overnight accommodation and travel are not included in the registration fee.




2017

As a result of the meeting we currently are involved in active negotiations with three companies we met there and are in question-answering stage with others. Almost too much interest for us to handle!! Washington University School of Medicine